Literature DB >> 36177265

Diverse imaging features of adolescent glioblastoma.

Thomas Campion1, Sara Stoneham2, Ayisha Al-Busaidi1, Atul Kumar3, Zane Jaunmuktane, Sebastian Brandner, Neil Kitchen4, Stefanie Thust.   

Abstract

We highlight an unusual case of multifocal glioblastoma in an adolescent patient, manifesting as four discrete brain lesions, each distinct in appearance. Familiarity with the diverse imaging features of glioblastoma can reduce misdiagnosis and avoid treatment delays.
© 2022 The Authors. Published by the British Institute of Radiology.

Entities:  

Year:  2021        PMID: 36177265      PMCID: PMC9499436          DOI: 10.1259/bjrcr.20210207

Source DB:  PubMed          Journal:  BJR Case Rep        ISSN: 2055-7159


Clinical presentation

A 17-year-old, previously well male was admitted to the emergency department with a 2-week history of progressive headaches, nausea and vomiting. This was followed by a single seizure with transient loss of consciousness. CT brain imaging performed on admission demonstrated several masses in both cerebral hemispheres (Figure 1). CT imaging of the chest, abdomen and pelvis identified no abnormality, and serum tumour markers (beta-HCG and alpha-fetoprotein) were negative.
Figure 1.

Pre- (a) and post-contrast (b) CT imaging performed on admission demonstrating bilateral cerebral tumours.

Pre- (a) and post-contrast (b) CT imaging performed on admission demonstrating bilateral cerebral tumours.

MR imaging findings

Four tumours varying in size and morphology were present within both cerebral hemispheres (Figure 2): Lesion 1 in the left superior parietal lobule appeared circumscript and markedly T2 hyperintense, showing restricted diffusion without Gadolinium contrast enhancement. Lesion 2 in the left inferior parietal lobule exhibited diffusivity similar to surrounding brain parenchyma and solid contrast enhancement. Lesion 3 was the largest, located at the right dorsal thalamic border. Because this lesion was centred on the lateral ventricular ependymal margin, it appeared partially intraventricular. Lesion 3 demonstrated avid peripheral contrast uptake with central necrosis. Lesion 4 consisted of ill-defined T2 hyperintense expansion of the right lentiform nucleus and surrounding brain parenchyma with patchy contrast uptake. Localised perilesional T2 signal abnormality (oedema ± infiltration) ranged from minimal to diffuse, with areas of normal appearing brain interposed between the lesions.
Figure 2.

T2 (a), ADC (b), T1+Gad (c) images showing multiple masses: Lesion 1 is circumscript with marked diffusion restriction and no significant Gadolinium enhancement. Lesion 2 is heterogenous featuring a rim of oedema/infiltration, ADC values similar to surrounding brain and avid enhancement. Lesion 3 exhibits rim enhancement and central necrosis. Lesion 4 is poorly marginated on all sequences demonstrating mild patchy Gadolinium uptake. ADC, apparent diffusion coefficient.

T2 (a), ADC (b), T1+Gad (c) images showing multiple masses: Lesion 1 is circumscript with marked diffusion restriction and no significant Gadolinium enhancement. Lesion 2 is heterogenous featuring a rim of oedema/infiltration, ADC values similar to surrounding brain and avid enhancement. Lesion 3 exhibits rim enhancement and central necrosis. Lesion 4 is poorly marginated on all sequences demonstrating mild patchy Gadolinium uptake. ADC, apparent diffusion coefficient.

Therapeutic management

The patient was transferred to the teenage and young adult (TYA) cancer unit, and a biopsy was performed. Histological examination showed morphological evidence of glioblastoma (WHO Grade IV). Post-operatively, the patient suffered a rapid clinical deterioration with increasing headaches, vomiting, blurred vision and new left arm paraesthesia and was commenced on steroids to help alleviate these symptoms. Upon histopathological assessment, immunohistochemical tests showed absence of the most common mutation of isocitrate dehydrogenase (IDH) 1 (R132H) (Figure 3), retained Alpha-thalassaemia X-linked mutant retardation (ATRX) protein expression in tumour cell nuclei, and a very high Ki67 proliferation index (Figure 3). On molecular pathological analysis,[1] the tumour was negative for rare IDH1 and for IDH2 (R172) mutations, BRAF (V600), or Histone 3.3 (K27, G34) mutations. Epidermal growth factor receptor was amplified (18 copies) and the methyl guanine methyl transferase (MGMT) promoter was unmethylated. The unusual presentation of a tumour, which is most commonly found in adults in their fifth-seventh decade, prompted us to perform a methylation array with subsequent algorithmic classification.[1] This investigation confirmed the presence of a classical IDH wild-type glioblastoma with the methylation subclass receptor tyrosine (RTK) kinase II.[2][3] The copy number profile (Figure 3) showed in addition a MYC amplification.
Figure 3.

Histology of the tumour shows a monomorphic population of neoplastic glial glial cells with frequent microvascular proliferations (arrow) (a). Immunoreactivity for mutant IDH1 (R132H) is negative (b) and ki67 immunostain for proliferating tumour cells shows a very high labelling index (c). The copy number profile, derived from the Illumina 450 K methylation array, shows the characteristic chromosome seven gain, 10q loss, and amplification of MYC and EGFR (d). The scale bar corresponds to 200 µm in (a)–(c). EGFR, epidermal growth factor receptor.

Histology of the tumour shows a monomorphic population of neoplastic glial glial cells with frequent microvascular proliferations (arrow) (a). Immunoreactivity for mutant IDH1 (R132H) is negative (b) and ki67 immunostain for proliferating tumour cells shows a very high labelling index (c). The copy number profile, derived from the Illumina 450 K methylation array, shows the characteristic chromosome seven gain, 10q loss, and amplification of MYC and EGFR (d). The scale bar corresponds to 200 µm in (a)–(c). EGFR, epidermal growth factor receptor. As a patient with this histological diagnosis and extent of disease is unlikely to be cured by resection, i.e. when the lesions involve multiple sites and are embedded in deep structures, rapid arc intensity-modulated targeted radiotherapy (54 Gy) was administered alongside adjuvant temozolomide, with palliative intent. Initially, a partial radiological response to treatment was observed, with complete symptom resolution. However, at 3 months into treatment a new gadolinium enhancing lesion developed in the dorsal medulla, indicating progressive disease. This new deposit and one of the previously treated cerebral lesions continued to grow. Temporary effective symptom control was achieved with further focal radiotherapy to the site of new disease, but disseminated ependymal and parenchymal disease followed, with death at 11 months post diagnosis.

Discussion

Glioblastoma is a relatively uncommon diagnosis in adolescence,[4] and it may be considered low on the differential list - more so if the imaging findings are perceived as atypical. We would like to draw attention to this case, in which the coexistence of several tumour morphologies could create a diagnostic dilemma. A learning point is to consider the possibility of malignant glioma in cases of multiple brain masses with different imaging appearances.[5] The diverse post Gadolinium (non-, solid-, rim-enhancing), T2 weighted (circumscript vs diffuse) and diffusion-weighted (restricted, intermediate, facilitated) features encountered in this case are all known to exist within the phenotypic spectrum of glioblastoma,[6,7] but may be confused with other entities, even dual pathology, when occurring in combination. Multifocal cerebral lesions may raise concern for infective-inflammatory aetiologies, especially in a young individual, metastatic disease or lymphoma.[8] Importantly, rapid progression can occur in glioblastoma and should not deter radiologists from suspecting the diagnosis.[9] Physiological MR imaging (perfusion, spectroscopy) can aid the diagnosis of glioblastoma,[10] however, in this case tissue diagnosis was prioritised because of the fulminant clinical decline. In adult patients, multiple intracranial tumours are present at diagnosis in up to 34% of glioblastomas.[11] It is probable that diverse glioblastoma morphologies represent different stages of the disease. Moreover, evidence exists for significant genetic heterogeneity amongst synchronous tumours[12] as well as within the same glioma through mutational evolution over time[13] ; glioblastomas have been shown to originate up to seven years before diagnosis and acquire most of their driver mutations leading to genetic heterogeneity in this period (i.e. before treatment is initiated).[14] Tumours involving the subventricular zone, as the presumed site of neural stem cell origin of glioblastoma, have been postulated to be more often multifocal and to recur at distant sites[15] ; in our case. the two lesions most closely related to the ventricular surface represented the sites of recurrence and progression. Multifocal glioblastoma typically have the IDH-wildtype genetic signature[16] associated with poor prognosis and limited response to maximum therapy. Multifocal disease may further shorten the dismal survival of glioblastoma, if gross total resection is difficult to achieve.[17,18] At present, most high-grade gliomas in adolescence undergo standard glioblastoma therapy, consisting of radiation and chemotherapy (Temozolomide). In the future, rapid genetic and epigenetic tumour profiling may improve focused approaches,[19] for which strategies in development include immune modulation and therapies directed against specific signalling pathways.[20]

Conclusion

Glioblastoma should be considered as part of the differential diagnosis in young patients presenting with multiple brain masses. The disease may exhibit variable MR imaging features, which can coexist in the same individual. Glioblastoma should be considered in young patients presenting with multiple brain masses. Glioblastoma manifests with variable MR imaging features, which can coexist in the same individual. Imaging findings include enhancing and non-enhancing lesions, with or without diffusion restriction.
  20 in total

1.  Clonal evolution of glioblastoma under therapy.

Authors:  Jiguang Wang; Emanuela Cazzato; Erik Ladewig; Veronique Frattini; Daniel I S Rosenbloom; Sakellarios Zairis; Francesco Abate; Zhaoqi Liu; Oliver Elliott; Yong-Jae Shin; Jin-Ku Lee; In-Hee Lee; Woong-Yang Park; Marica Eoli; Andrew J Blumberg; Anna Lasorella; Do-Hyun Nam; Gaetano Finocchiaro; Antonio Iavarone; Raul Rabadan
Journal:  Nat Genet       Date:  2016-06-06       Impact factor: 38.330

2.  Genetic investigation of multicentric glioblastoma multiforme: case report.

Authors:  Brett Schroeder; Nameeta Shah; Steve Rostad; Brendan McCullough; Brian Aguedan; Greg Foltz; Charles Cobbs
Journal:  J Neurosurg       Date:  2015-10-16       Impact factor: 5.115

3.  Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.

Authors:  Barbara C Worst; Cornelis M van Tilburg; Gnana Prakash Balasubramanian; Petra Fiesel; Ruth Witt; Angelika Freitag; Miream Boudalil; Christopher Previti; Stephan Wolf; Sabine Schmidt; Sasithorn Chotewutmontri; Melanie Bewerunge-Hudler; Matthias Schick; Matthias Schlesner; Barbara Hutter; Lenka Taylor; Tobias Borst; Christian Sutter; Claus R Bartram; Till Milde; Elke Pfaff; Andreas E Kulozik; Arend von Stackelberg; Roland Meisel; Arndt Borkhardt; Dirk Reinhardt; Jan-Henning Klusmann; Gudrun Fleischhack; Stephan Tippelt; Uta Dirksen; Heribert Jürgens; Christof M Kramm; Andre O von Bueren; Frank Westermann; Matthias Fischer; Birgit Burkhardt; Wilhelm Wößmann; Michaela Nathrath; Stefan S Bielack; Michael C Frühwald; Simone Fulda; Thomas Klingebiel; Ewa Koscielniak; Matthias Schwab; Roman Tremmel; Pablo Hernáiz Driever; Johannes H Schulte; Benedikt Brors; Andreas von Deimling; Peter Lichter; Angelika Eggert; David Capper; Stefan M Pfister; David T W Jones; Olaf Witt
Journal:  Eur J Cancer       Date:  2016-07-29       Impact factor: 9.162

4.  Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis.

Authors:  Verena Körber; Jing Yang; Pankaj Barah; Yonghe Wu; Damian Stichel; Zuguang Gu; Michael Nai Chung Fletcher; David Jones; Bettina Hentschel; Katrin Lamszus; Jörg Christian Tonn; Gabriele Schackert; Michael Sabel; Jörg Felsberg; Angela Zacher; Kerstin Kaulich; Daniel Hübschmann; Christel Herold-Mende; Andreas von Deimling; Michael Weller; Bernhard Radlwimmer; Matthias Schlesner; Guido Reifenberger; Thomas Höfer; Peter Lichter
Journal:  Cancer Cell       Date:  2019-03-21       Impact factor: 31.743

5.  Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England.

Authors:  Ramandeep S Arora; Robert D Alston; Tim O B Eden; Edward J Estlin; Anthony Moran; Jillian M Birch
Journal:  Neuro Oncol       Date:  2008-11-24       Impact factor: 12.300

Review 6.  Perfusion MRI as a diagnostic biomarker for differentiating glioma from brain metastasis: a systematic review and meta-analysis.

Authors:  Chong Hyun Suh; Ho Sung Kim; Seung Chai Jung; Choong Gon Choi; Sang Joon Kim
Journal:  Eur Radiol       Date:  2018-04-04       Impact factor: 5.315

7.  Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype.

Authors:  Daniel A Lim; Soonmee Cha; Mary C Mayo; Mei-Hsiu Chen; Evren Keles; Scott VandenBerg; Mitchel S Berger
Journal:  Neuro Oncol       Date:  2007-07-10       Impact factor: 12.300

8.  Novel drugs in pediatric gliomas.

Authors:  Dongli Zhang; Xiaoming Liu; Conghai Fan; Jiao Chen
Journal:  Oncol Lett       Date:  2017-03-06       Impact factor: 2.967

9.  DNA methylation-based classification of central nervous system tumours.

Authors:  David Capper; David T W Jones; Martin Sill; Volker Hovestadt; Daniel Schrimpf; Dominik Sturm; Christian Koelsche; Felix Sahm; Lukas Chavez; David E Reuss; Annekathrin Kratz; Annika K Wefers; Kristin Huang; Kristian W Pajtler; Leonille Schweizer; Damian Stichel; Adriana Olar; Nils W Engel; Kerstin Lindenberg; Patrick N Harter; Anne K Braczynski; Karl H Plate; Hildegard Dohmen; Boyan K Garvalov; Roland Coras; Annett Hölsken; Ekkehard Hewer; Melanie Bewerunge-Hudler; Matthias Schick; Roger Fischer; Rudi Beschorner; Jens Schittenhelm; Ori Staszewski; Khalida Wani; Pascale Varlet; Melanie Pages; Petra Temming; Dietmar Lohmann; Florian Selt; Hendrik Witt; Till Milde; Olaf Witt; Eleonora Aronica; Felice Giangaspero; Elisabeth Rushing; Wolfram Scheurlen; Christoph Geisenberger; Fausto J Rodriguez; Albert Becker; Matthias Preusser; Christine Haberler; Rolf Bjerkvig; Jane Cryan; Michael Farrell; Martina Deckert; Jürgen Hench; Stephan Frank; Jonathan Serrano; Kasthuri Kannan; Aristotelis Tsirigos; Wolfgang Brück; Silvia Hofer; Stefanie Brehmer; Marcel Seiz-Rosenhagen; Daniel Hänggi; Volkmar Hans; Stephanie Rozsnoki; Jordan R Hansford; Patricia Kohlhof; Bjarne W Kristensen; Matt Lechner; Beatriz Lopes; Christian Mawrin; Ralf Ketter; Andreas Kulozik; Ziad Khatib; Frank Heppner; Arend Koch; Anne Jouvet; Catherine Keohane; Helmut Mühleisen; Wolf Mueller; Ute Pohl; Marco Prinz; Axel Benner; Marc Zapatka; Nicholas G Gottardo; Pablo Hernáiz Driever; Christof M Kramm; Hermann L Müller; Stefan Rutkowski; Katja von Hoff; Michael C Frühwald; Astrid Gnekow; Gudrun Fleischhack; Stephan Tippelt; Gabriele Calaminus; Camelia-Maria Monoranu; Arie Perry; Chris Jones; Thomas S Jacques; Bernhard Radlwimmer; Marco Gessi; Torsten Pietsch; Johannes Schramm; Gabriele Schackert; Manfred Westphal; Guido Reifenberger; Pieter Wesseling; Michael Weller; Vincent Peter Collins; Ingmar Blümcke; Martin Bendszus; Jürgen Debus; Annie Huang; Nada Jabado; Paul A Northcott; Werner Paulus; Amar Gajjar; Giles W Robinson; Michael D Taylor; Zane Jaunmuktane; Marina Ryzhova; Michael Platten; Andreas Unterberg; Wolfgang Wick; Matthias A Karajannis; Michel Mittelbronn; Till Acker; Christian Hartmann; Kenneth Aldape; Ulrich Schüller; Rolf Buslei; Peter Lichter; Marcel Kool; Christel Herold-Mende; David W Ellison; Martin Hasselblatt; Matija Snuderl; Sebastian Brandner; Andrey Korshunov; Andreas von Deimling; Stefan M Pfister
Journal:  Nature       Date:  2018-03-14       Impact factor: 49.962

10.  Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre.

Authors:  Zane Jaunmuktane; David Capper; David T W Jones; Daniel Schrimpf; Martin Sill; Monika Dutt; Nirosha Suraweera; Stefan M Pfister; Andreas von Deimling; Sebastian Brandner
Journal:  Acta Neuropathol Commun       Date:  2019-02-20       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.